Article
Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.
Oncology reports - 1 May 2014
Seo Yuki, Ishii Yoshiyuki, Ochiai Hiroki, Fukuda Kazumasa, Akimoto Shingo, Hayashida Tetsu, Okabayashi Koji, Tsuruta Masashi, Hasegawa Hirotoshi, Kitagawa Yuko
Abstract excerpt
Cetuximab, an IgG1 monoclonal antibody against the epidermal growth factor receptor (EGFR), is widely used for the treatment of metastatic colorectal cancer (mCRC). One of the mechanisms of action is considered to be antibody-dependent cell-mediated cytotoxicity (ADCC) triggered by Fcγ-R on natural killer cells. However, whether ADCC is associated with EGFR expression and/or the mutational status of EGF...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.